BRPI0911604A2 - vacinas de polipeptídeo de flagelina - Google Patents

vacinas de polipeptídeo de flagelina

Info

Publication number
BRPI0911604A2
BRPI0911604A2 BRPI0911604A BRPI0911604A BRPI0911604A2 BR PI0911604 A2 BRPI0911604 A2 BR PI0911604A2 BR PI0911604 A BRPI0911604 A BR PI0911604A BR PI0911604 A BRPI0911604 A BR PI0911604A BR PI0911604 A2 BRPI0911604 A2 BR PI0911604A2
Authority
BR
Brazil
Prior art keywords
flagellin polypeptide
polypeptide vaccines
vaccines
flagellin
polypeptide
Prior art date
Application number
BRPI0911604A
Other languages
English (en)
Inventor
Alan A Aderem
Alan H Diercks
Carrie M Rosenberger
Edward A Miao
Original Assignee
Inst Systems Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Systems Biology filed Critical Inst Systems Biology
Publication of BRPI0911604A2 publication Critical patent/BRPI0911604A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16061—Methods of inactivation or attenuation
    • C12N2760/16062—Methods of inactivation or attenuation by genetic engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BRPI0911604A 2008-04-25 2009-04-24 vacinas de polipeptídeo de flagelina BRPI0911604A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4810008P 2008-04-25 2008-04-25
PCT/IB2009/006511 WO2009130618A2 (en) 2008-04-25 2009-04-24 Flagellin polypeptide vaccines

Publications (1)

Publication Number Publication Date
BRPI0911604A2 true BRPI0911604A2 (pt) 2015-12-15

Family

ID=41217205

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0911604A BRPI0911604A2 (pt) 2008-04-25 2009-04-24 vacinas de polipeptídeo de flagelina

Country Status (6)

Country Link
US (1) US20090297552A1 (pt)
EP (1) EP2278994A4 (pt)
JP (1) JP2011519834A (pt)
CN (1) CN102046198A (pt)
BR (1) BRPI0911604A2 (pt)
WO (1) WO2009130618A2 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8420102B2 (en) 2006-03-07 2013-04-16 Vaxinnate Corporation Compositions that include hemagglutinin
EP2374474A1 (en) 2005-01-19 2011-10-12 Vaxinnate Corporation Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
AU2009236585B2 (en) 2008-04-18 2013-03-07 Vaxinnate Corporation Deletion mutants of flagellin and methods of use
US20100322957A1 (en) * 2009-05-22 2010-12-23 Aderem Alan A Secretion-related bacterial proteins for nlrc4 stimulation
WO2010141312A2 (en) * 2009-06-01 2010-12-09 Wake Forest University Health Sciences Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
JP2013516469A (ja) * 2010-01-06 2013-05-13 ヴァクシネイト コーポレイション 高齢者に保護免疫を提供するための方法及び組成物
BR112012033121B1 (pt) * 2010-06-25 2019-08-20 Institut Pasteur De Lille Métodos e composições farmacêuticas para o tratamento de infecções do trato respiratório.
WO2012025831A2 (en) * 2010-08-24 2012-03-01 The University Of British Columbia Salmonella vaccine proteins
WO2012040164A2 (en) * 2010-09-24 2012-03-29 Emory University Tlr5 ligands, therapeutic methods, and compositions related thereto
FR2969657B1 (fr) 2010-12-22 2014-02-07 Fabre Pierre Dermo Cosmetique Nouvelle bacterie et extraits de ladite bacterie et leur utilisation en dermatologie
FR2969658B1 (fr) 2010-12-22 2014-10-17 Fabre Pierre Dermo Cosmetique Nouvelle bacterie et extraits de ladite bacterie et leur utilisation therapeutique
JP5876930B2 (ja) * 2011-07-05 2016-03-02 蘇州科景生物医薬科技有限公司 炎症性腸疾患の予防および治療のための薬物の調製におけるサルモネラフラゲリン誘導体の使用
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
CN102993301B (zh) * 2012-12-11 2014-02-26 北京出入境检验检疫局检验检疫技术中心 霍乱弧菌鞭毛蛋白单克隆抗体及抗原捕获elisa试剂盒
WO2015102936A1 (en) * 2013-12-30 2015-07-09 V-Core Technologies, Inc. Poxvirus-plasmodium recombinants, compositions containing such recombinants, uses thereof, and methods of making and using same
US20180133327A1 (en) * 2015-03-16 2018-05-17 Amal Therapeutics Sa Cell Penetrating Peptides and Complexes Comprising the Same
WO2017024292A1 (en) * 2015-08-06 2017-02-09 The Regents Of The University Of California Hybrid flagellin as a t cell independent vaccine scaffold
CN108139401B (zh) * 2015-09-25 2022-02-18 凯杰科技有限公司 诊断莱姆病并用于预测治疗后莱姆病螺旋体消除的组合物和方法
CN108135992A (zh) * 2015-10-21 2018-06-08 米纳瓦克斯有限责任公司 免疫原性融合蛋白
WO2017079653A2 (en) * 2015-11-06 2017-05-11 Vetica Labs, Inc. Methods of detecting inflammatory markers and treating inflammatory conditions in companion animals
PL3429618T3 (pl) 2016-03-16 2024-07-01 Amal Therapeutics Sa Kombinacja modulatora immunologicznego punktu kontrolnego i kompleks zawierający peptyd penetrujący komórkę, cargo i agonistę peptydu tlr do zastosowania w medycynie
HUE067838T2 (hu) 2016-09-21 2024-11-28 Amal Therapeutics Sa Egy sejtpenetráló peptidet, egy multiepitópot és egy TLR peptidagonistát tartalmazó fúzió rák kezelésére
KR101875055B1 (ko) * 2016-10-19 2018-07-06 연세대학교 원주산학협력단 융합 단백질 및 그의 용도
CN108218965B (zh) * 2016-12-22 2021-04-30 新疆农业大学 一种马流产沙门氏菌鞭毛蛋白FliC的制备方法和应用
WO2019018768A1 (en) 2017-07-20 2019-01-24 Spogen Biotech Inc. BIOACTIVE POLYPEPTIDES FOR PLANT PROTECTION, GROWTH AND PRODUCTIVITY ENHANCEMENTS
WO2019180051A1 (en) 2018-03-19 2019-09-26 4D Pharma Research Limited Compositions comprising bacterial strains
CN108478788A (zh) * 2018-04-23 2018-09-04 武汉中拓康明生物科技有限公司 Cap-TFlg蛋白在制备PCV2疫苗中的应用
CN109627298B (zh) * 2018-11-23 2020-12-18 武汉大学 一种具有抗hiv-1作用的重组鞭毛蛋白及其编码基因和应用
WO2020110154A1 (en) * 2018-11-30 2020-06-04 Bharat Biotech International Limited A chimeric therapeutic vaccine
CA3170478A1 (en) * 2020-03-05 2021-09-10 James E. Galen Live salmonella typhi vectors engineered to express cancer protein antigens and methods of use thereof
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
CN114703115B (zh) * 2022-04-22 2023-09-29 集美大学 一种变形假单胞菌fliS基因沉默菌株和用途
CN116496406B (zh) * 2022-07-13 2023-11-03 河北省肿瘤研究所 激活tlr-5的幽门螺旋杆菌融合抗原及其应用
WO2026022365A1 (en) * 2024-07-26 2026-01-29 Elanco Animal Health Gmbh Mammalian il-4/il-13/flagellin constructs

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127331A0 (en) * 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
US6593292B1 (en) * 1999-08-24 2003-07-15 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US20030175287A1 (en) * 2001-01-03 2003-09-18 Yale University Innate immune system-directed vaccines
US8703146B2 (en) * 2001-04-20 2014-04-22 Institute For Systems Biology Toll-like receptor 5 ligands and methods of use
EP1536832A2 (en) * 2002-09-03 2005-06-08 Fondation Eurovacc Flagellin peptides as adjuvants for vaccines
US20080248068A1 (en) * 2004-05-07 2008-10-09 Hans-Gustaf Ljunggren Use of Flagellin as an Adjuvant for Vaccine
EP1827489B1 (en) * 2004-12-16 2012-10-31 Wake Forest University Health Sciences Use of flagellin in tumor immunotherapy
EP2374474A1 (en) * 2005-01-19 2011-10-12 Vaxinnate Corporation Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
WO2007103048A2 (en) * 2006-03-01 2007-09-13 Regents Of The University Of Colorado Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
US20110052635A1 (en) * 2006-03-20 2011-03-03 Vrije Universiteit Brussel Live attenuated salmonella vaccine
US20080038297A1 (en) * 2006-04-26 2008-02-14 Gupta Kalpana Genetic adjuvants for viral vaccines
WO2007125535A1 (en) * 2006-05-01 2007-11-08 Biondvax Pharmaceuticals Ltd. Recombinant flagellin gene and uses thereof
DK2133092T3 (en) * 2007-03-19 2016-01-11 Morishita Jintan Co Oral vaccine

Also Published As

Publication number Publication date
WO2009130618A3 (en) 2010-10-07
CN102046198A (zh) 2011-05-04
US20090297552A1 (en) 2009-12-03
WO2009130618A2 (en) 2009-10-29
EP2278994A2 (en) 2011-02-02
EP2278994A4 (en) 2012-01-18
JP2011519834A (ja) 2011-07-14

Similar Documents

Publication Publication Date Title
BRPI0911604A2 (pt) vacinas de polipeptídeo de flagelina
EP2276499A4 (en) ANTIGEN OF RECOMBINANT GLIADINE DEAMIDED
PL2465864T3 (pl) Szczepionki z peptydem pochodzącym z Eph4
DK2114993T3 (da) Vaccine
IL211184A0 (en) Polyvalent vaccine
ATE450271T1 (de) Impfstoff
PT2406399T (pt) Proteínas mirac
HRP20181347T1 (hr) Formulacije dvoslojne tablete
HUE031343T2 (hu) Immunitásindukáló ágens
EP2296593A4 (en) MEDICAL HEAD COVER
BRPI0918097A2 (pt) dispositivo respiratório de interface
BR112012030950A2 (pt) formulações de vacina
DK2335370T3 (da) Organ-på-en-chip-anordning
BRPI0920521A2 (pt) combinação farmacêutica
DK2235384T3 (da) Forbindelsesindretning
CR10571A (es) Vacuna virica recombinante
BRPI1009465A2 (pt) Formulação
BRPI0920240A2 (pt) formulação de adjuvante de combinação
DK2837348T3 (da) Kryokirurgiske fremgangsmåder
ES1067341Y (es) Dispositivo perforador-fijador
BRPI1010661A2 (pt) peptídeo
DE112009000863A5 (de) Steckvorrichtung
HUE054030T2 (hu) Fejlesztett formulációk
EP2207567A4 (en) IMMUNOGENIC FORMULATIONS
BRPI0921578A2 (pt) vacinas unitemporais

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.